Ontology highlight
ABSTRACT: Introduction
Established personal and familial risk factors contribute collectively to a woman's risk of breast or ovarian cancer. Existing clinical services offer genetic testing for pathogenic variants in high-risk genes to investigate these risks but recent information on the role of common genomic variants, in the form of a Polygenic Risk Score (PRS), has provided the potential to further personalise breast and ovarian cancer risk assessment. Data from cohort studies support the potential of an integrated risk assessment to improve targeted risk management but experience of this approach in clinical practice is limited.Methods and analysis
The polygenic risk modification trial is an Australian multicentre prospective randomised controlled trial of integrated risk assess
SUBMITTER: McInerny S
PROVIDER: S-EPMC11308879 | biostudies-literature | 2024 Aug
REPOSITORIES: biostudies-literature